Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letters to the Editor
  • Published:

Still more debate over VEGF

Nature Medicine volume 7, pages 639–640 (2001)Cite this article

To the editor

Celletti et al. have recently reported in Nature Medicine (and identical portions of the results are soon to be reported in the Journal of the American College of Cardiology) that recombinant human vascular endothelial growth factor (rhVEGF) can promote atherosclerosis in the thoracic aortae of mice and rabbits1. Interpretation of these findings requires a broader perspective than has been provided by the authors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Celletti, F.L. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Med. 7, 425–429 (2001).

    Article  CAS  Google Scholar 

  2. Van Belle, E. et al. Stent endothelialization: time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation 95, 438–448 (1997).

    Article  CAS  Google Scholar 

  3. Van Belle, E. et al. Passivation of metallic stents following arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J. Am. Coll. Cardiol. 29, 1371–1379 (1997).

    Article  CAS  Google Scholar 

  4. Van Belle, E., Maillard, L., Tio, F.O. & Isner, J.M. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem. Biophys. Res. Comm. 235, 311–316 (1997).

    Article  CAS  Google Scholar 

  5. Asahara, T. et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91, 2793–2801 (1995).

    Article  CAS  Google Scholar 

  6. Asahara, T. et al. Accelerated restitution of endothelial integrity and endothelium-dependent function following phVEGF165 gene transfer. Circulation 94, 3291–3302 (1996).

    Article  CAS  Google Scholar 

  7. Tsurumi, Y. et al. Reciprocal relationship between VEGF and NO in the regulation of endothelial integrity. Nature Med. 3, 879–886 (1997).

    Article  CAS  Google Scholar 

  8. Hiltunen, M.O. et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 102, 2262–2268 (2000).

    Article  CAS  Google Scholar 

  9. Isner, J.M. et al. Clinical evidence of angiogenesis following arterial gene transfer of phVEGF165 . Lancet 348, 370–374 (1996).

    Article  CAS  Google Scholar 

  10. Isner, J.M. Arterial gene transfer for naked DNA for therapeutic angiogenesis: early clinical results. Adv. Drug. Deliv. Rev. 30,185–197 (1998).

    Article  CAS  Google Scholar 

  11. Vale, P.R. et al. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty. Circulation 98, I-66 (1998).

    Google Scholar 

  12. Minar, E. et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 102, 2694–2699 (2000).

    Article  CAS  Google Scholar 

  13. Laitinen, M. et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther. 11, 263–270 (2000).

    Article  CAS  Google Scholar 

  14. Luo, Z., Asahara, T., Tsurumi, Y., Isner, J.M. & Symes, J.F. Reduction of vein graft intimal hyperplasia and preservation of endothelium-dependent relaxation by topical vascular endothelial growth factor. J. Vasc. Surg. 27, 167–173 (1998).

    Article  CAS  Google Scholar 

  15. Henry, T.D. et al. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor—the VIVA trial. J. Am. Coll. Cardiol. 33, 384A (1999).

    Google Scholar 

  16. Lazarous, D.F. et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 94, 1074–1082 (1996).

    Article  CAS  Google Scholar 

  17. Moulton, K.S. et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99, 1726–1732 (1999).

    Article  CAS  Google Scholar 

  18. Ware, J.A. Too many vessels? Not Enough? The wrong kind? The VEGF debate continues. Nature Medicine 7, 403–404 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Elizabeth's Medical Center Tufts University School of Medicine, Boston, Massachusetts, USA

    Jeffrey M. Isner

Authors
  1. Jeffrey M. Isner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isner, J. Still more debate over VEGF. Nat Med 7, 639–640 (2001). https://doi.org/10.1038/88966

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/88966

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing